BRIEF published on 04/17/2026 at 09:43, 3 months 20 days ago Heidelberg Pharma annonce un changement au sein de son conseil d'administration. Biotechnologie Essai Clinique Nomination Du Directeur Financier Heidelberg Pharma Changement Exécutif
PRESS RELEASE published on 04/17/2026 at 09:38, 3 months 20 days ago Heidelberg Pharma Announces Change in Executive Board Heidelberg Pharma announces change in Executive Board as CFO Walter Miller departs end of April, Peter Willinger appointed as new CFO from 1 May 2026. Company specializes in developing Antibody Drug Conjugates (ADCs) CFO Executive Board Heidelberg Pharma Antibody Drug Conjugates ADCs
BRIEF published on 04/09/2026 at 14:31, 3 months 28 days ago Heidelberg Pharma fait progresser son candidat ADC HDP-101 vers la phase II des essais cliniques. Heidelberg Pharma Essai De Phase II Recherche Clinique Myélome Multiple ADC HDP-101
BRIEF published on 04/09/2026 at 14:31, 3 months 28 days ago Heidelberg Pharma Advances ADC Candidate HDP-101 to Phase II Trial Clinical Research Heidelberg Pharma Phase II Trial Multiple Myeloma ADC HDP-101
PRESS RELEASE published on 04/09/2026 at 14:26, 3 months 28 days ago EQS-Adhoc: Heidelberg Pharma AG: Heidelberg Pharma Determines Recommended Dose for Phase II Trial with ADC Candidate HDP-101 Heidelberg Pharma AG determines recommended Phase II dose for ADC candidate HDP-101 in multiple myeloma trial, plans Phase IIa initiation shortly Heidelberg Pharma AG Multiple Myeloma ADC Candidate Phase II Dose Phase IIa Trial
BRIEF published on 04/04/2026 at 10:12, 4 months 3 days ago Heidelberg Pharma to Showcase ADC Technology at AACR 2026 Heidelberg Pharma ADC Technology Prostate Cancer AACR 2026 HDP-103
BRIEF published on 04/04/2026 at 10:12, 4 months 3 days ago Heidelberg Pharma présentera sa technologie ADC lors du congrès AACR 2026 Heidelberg Pharma Cancer De La Prostate Technologie ADC AACR 2026 HDP-103
PRESS RELEASE published on 04/04/2026 at 10:07, 4 months 3 days ago Heidelberg Pharma to Present Data from its ADC Technology Platform at AACR Annual Meeting 2026 Heidelberg Pharma to present promising preclinical data of Amanitin-based ADC HDP-103 targeting mCRPC at AACR Annual Meeting 2026 in San Diego Heidelberg Pharma Amanitin-based ADC ADC Technology Platform AACR Annual Meeting 2026 MCRPC
BRIEF published on 03/26/2026 at 07:12, 4 months 12 days ago Heidelberg Pharma publie ses résultats financiers pour 2025 et ses perspectives pour 2026. Résultats Financiers Heidelberg Pharma Mesures De Réduction Des Coûts Technologie ADC Perspectives 2026
BRIEF published on 03/26/2026 at 07:12, 4 months 12 days ago Heidelberg Pharma Publishes 2025 Financial Results and 2026 Outlook Financial Results Cost-cutting Measures Heidelberg Pharma ADC Technology 2026 Outlook
Published on 08/07/2026 at 23:15, 1 hour 27 minutes ago Faraday Copper Reports Second Quarter 2026 Financial Results
Published on 08/07/2026 at 23:00, 1 hour 42 minutes ago Rio Grande Resources Announces up to $2,500,000 Non-Brokered Private Placement Financing
Published on 08/07/2026 at 22:30, 2 hours 12 minutes ago UraniumX Deploys $3.8 Million to Athabasca Basin Exploration
Published on 08/07/2026 at 22:15, 2 hours 27 minutes ago Noram Lithium Engages 1353656 BC Ltd. for Marketing and Management Consulting Services
Published on 08/07/2026 at 23:21, 1 hour 21 minutes ago EQS-Adhoc: Northern Data Group reports Q2 2026 including the adverse fair value movement on contingent consideration
Published on 08/07/2026 at 19:30, 5 hours 12 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 08/07/2026 at 19:15, 5 hours 27 minutes ago ABO Energy Agrees Sale of Its Polish and Hungarian Subsidiaries
Published on 08/07/2026 at 18:10, 6 hours 32 minutes ago Stabilus SE: Andreas Jaeger steps down as Chief Financial Officer at his own request
Published on 08/07/2026 at 18:00, 6 hours 42 minutes ago E-PANGO: Composition du capital au 31 juillet 2026
Published on 08/07/2026 at 18:54, 5 hours 48 minutes ago Covivio - Déclaration des transactions sur actions propres réalisées du 03 août 2026 au 07 août 2026
Published on 08/07/2026 at 18:54, 5 hours 48 minutes ago Covivio - Information on Treasury shares transactions between August 3rd, 2026, and August 7th, 2026
Published on 08/07/2026 at 18:40, 6 hours 2 minutes ago Disclosure of transactions in own shares from August 3 to August 7, 2026
Published on 08/07/2026 at 18:40, 6 hours 2 minutes ago Déclaration hebdomadaire d'opérations effectuées du 3 au 7 août 2026
Published on 08/07/2026 at 18:00, 6 hours 42 minutes ago LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 juillet 2026
